Breaking news

AstraZeneca Bolsters Cancer Treatment Capabilities With $1 Billion EsoBiotec Acquisition

The renowned British pharmaceutical company, AstraZeneca, has announced a striking move by acquiring Belgium’s EsoBiotec for an impressive sum of up to $1 billion. This acquisition is expected to significantly boost AstraZeneca’s expertise in cancer treatment formulations.

This ambitious move consists of an immediate payment of $425 million with the potential to invest an additional $575 million to meet developmental and regulatory milestones. This strategic acquisition fully supports AstraZeneca’s vision of revolutionizing cancer treatment through cutting-edge cellular therapy.

EsoBiotec’s platform is renowned for its transformative approach to cellular therapy, aiming to enhance the body’s immune defenses against cancer cells. By engineering immune cells directly within the patient’s body utilizing targeted viruses, what once took weeks for treatment could now potentially be reduced to mere minutes—a groundbreaking leap in medical technology!

Following the conclusion of this deal by the second quarter of 2025, EsoBiotec will operate as a subsidiary under AstraZeneca, continuing its innovative work from Belgium. This move aligns seamlessly with AstraZeneca’s commitment to advancing healthcare and providing innovative solutions in the realm of oncology.

Furthering The Fight Against Cancer

On the same day, AstraZeneca also announced an agreement to license multiple oncology assets from Alteogen. Such strategic partnerships underscore AstraZeneca’s dedication to pioneering advances in cancer treatment.

For more insightful developments such as these, explore the latest Biobank.cy’s Nano-Innovation Sets A New Standard In Targeted Breast Cancer Treatment.

Mirendil Signs $100 Million Google Cloud Deal To Advance Self-Improving AI

AI startup Mirendil has signed a multi-year agreement worth more than $100 million with Google Cloud to secure computing infrastructure for its self-improving AI research.

The partnership reflects growing competition among AI companies to lock in access to high-performance computing, while cloud providers race to attract promising startups developing next-generation AI models.

Backing The Next Stage Of AI Research

Mirendil plans to use Google’s Tensor Processing Units (TPUs), Nvidia GPUs and managed training infrastructure to develop AI systems capable of improving their own performance over time.

Known as recursive self-improvement, the concept focuses on building AI that can refine its knowledge and capabilities with minimal human intervention. The technology is attracting growing interest across the industry, with several startups and leading AI labs exploring similar approaches.

According to co-founder and Chief Executive Behnam Neyshabur, the long-term goal is to develop AI that can automate scientific research and accelerate discoveries in fields such as medicine, biology and materials science.

Compute Capacity Becomes A Strategic Asset

Training increasingly advanced AI models requires enormous computing resources, making long-term infrastructure agreements a critical competitive advantage.

Mirendil said Google’s combination of TPUs and GPUs allows workloads to be matched with the most suitable hardware, improving efficiency while reducing costs for customers.

For Google Cloud, the agreement strengthens its position in the race to provide infrastructure for frontier AI developers, while giving the company exposure to one of the industry’s emerging approaches to next-generation artificial intelligence.

eCredo
The Future Forbes Realty Global Properties
Aretilaw firm
Uol

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter